Mylan Pays $465M To Settle With DOJ Over EpiPen Medicaid Rebates, Details Unclear

Mylan is paying $465 million to settle with the Justice Department over EpiPen Medicaid rebates, the company announced late Friday (Oct. 7) while not specifying how much of that will go back to the states. The settlement resolves all potential rebate liability claims by federal and state governments over whether EpiPen should have been subject to higher rebates, and Mylan's stock shot up 10 percent in after-hour trading as of this writing. Mylan, which admitted no wrongdoing in classifying EpiPen...